Alice announced that in the first half of 2026, it achieved total operating revenue of 3.320 billion yuan, an increase of 39.85%; net profit to mother of 1,541 million yuan, an increase of 46.57% over the previous year; and total R&D investment of 254 million yuan. The development and commercialization of the core product vometinib for multiple indications is progressing smoothly. The company plans to distribute a cash dividend of 6.00 yuan for every 10 shares to all shareholders, for a total of 270 million yuan in discovery dividends.

Alice announced that in the first half of 2026, it achieved total operating revenue of 3.320 billion yuan, an increase of 39.85%; net profit to mother of 1,541 million yuan, an increase of 46.57% over the previous year; and total R&D investment of 254 million yuan. The development and commercialization of the core product vometinib for multiple indications is progressing smoothly. The company plans to distribute a cash dividend of 6.00 yuan for every 10 shares to all shareholders, for a total of 270 million yuan in discovery dividends.